Differentiation of plasmocytic responses from myelomatous diseases on the basis of bone-marrow findings

Fadem, Robert S.

doi:10.1002/1097-0142(195201)5:1<128::aid-cncr2820050117>3.0.co;2-g

Cited by 31 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T h e Mglobulins found in this study were each accompanied by hyperplasia of plasma cells or lymphocytes that normally produce immunoglobulins. T h e antigenic types of M-proteins found in cases 6, 7,8 and 11 with disseminated cancer are similar to those found in myeloma or macroglobulinemia. These types here included IgM (case 6), IgG (case 7), IgA (case 8) and Bence Jones (case 11).…”

supporting

confidence: 72%

M-proteins, plasmacytosis and cancer

Hosley

1967

Cancer

View full text Add to dashboard Cite

Fourteen cancer patients with a discrete increase in serum protein on paper electrophoresis were studied for the presence of multiple myeloma. The abnormal proteins were indistinguishable from globulins produced in patients with myeloma. Five cases had osteolytic bone lesions and appeared to have coincident myeloma. One case had metastatic osteolytic disease and 8 cases were free of bone disease on roentgenogram. All cases had abnormal bone marrows with varying increases in lymphocytes and plasma cells. A unifying concept was that hyperplasia of a single clone of plasma cells or lymphocytes had occurred in each case either independent of or for factors related to the malignancy. It appeared that in the absence of secondary bone destruction, clonal hyperplasia did not necessarily represent malignancy of the immunocytic cell.

show abstract

supporting

confidence: 72%

M-proteins, plasmacytosis and cancer

Hosley

1967

Cancer

View full text Add to dashboard Cite

show abstract

“…Cases of multiple myeloma (MM) occurring in the setting of inflammatory bowel disease have been reported. As far back as 1952, Fadem presented a case in which ulcerative colitis was accompanied by plasmacytosis [3]. In 1964, a time when the criteria for diagnosing multiple myeloma differed markedly from those used currently, Bernstein and Dixon discussed a patient with ulcerative colitis who was diagnosed with MM based on marrow plasmacytosis of 19.5-21.5% [4].…”

mentioning

confidence: 99%

Review Article: Multiple Myeloma and Inflammatory Bowel Disease

2007

View full text Add to dashboard Cite

Since 1964 only nine cases of multiple myeloma occurring in the setting of inflammatory bowel disease have been reported. Although this occurrence may be a mere unfortunate coincidence, there are sound pathophysiological reasons for such an event. The possibility that chronic inflammatory conditions, immunomodulator therapy, and infliximab can predispose to multiple myeloma and lymphoma is reviewed. We discuss in detail the only reported case of multiple myeloma arising in the setting of infliximab treatment for Crohn's disease. It is highly probable that infliximab therapy had a causal role in our patient developing multiple myeloma. The pathogenesis of multiple myeloma arising in the setting of infliximab therapy may be related to decreased apoptosis of plasma cell populations. Since it is possible that a causal association exists between infliximab therapy and multiple myeloma, additional screening measures may be required in patients with Crohn's disease on infliximab.

show abstract

“…Several cases of IBD associated with MM have been reported in the literature. Fadem et al reported a case of plasmacytoma in a patient with UC [ 35 ]. In the mid-1960s, Bernstein and Dixon discussed a patient with UC who was diagnosed with MM [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Association between Multiple Myeloma and Ulcerative Colitis: A Cross-Sectional Analysis

et al. 2023

View full text Add to dashboard Cite

Background and Aims: Multiple myeloma (MM) is a plasma cell dyscrasia that is common among patients with autoimmune diseases. However, the association between ulcerative colitis (UC) and multiple myeloma (MM) is yet to be established. We aimed to evaluate the prevalence of MM among patients with UC in the United States. Methods: This cross-sectional cohort analysis used the National Inpatient Sample from 2015–2018 to assess the overall MM prevalence among patients with and without UC, and within specific demographic subgroups. Prevalences were compared using a logistic regression model controlling for sex and age. Results: The crude prevalence of MM among patients with UC (n = 1750) compared with patients without UC (n = 366,265) was 0.44% vs. 0.37%, respectively. Patients with UC had increased overall odds of having MM (odds ratio (OR), 1.26). Males with UC had higher prevalence of MM (53.7% vs. 46.3%, respectively) than females. Patients with UC and MM were more likely to be African American than White (15.6% vs. 9.2%, respectively). Patients with UC age >64 had a higher prevalence of MM than those aged below 65 (70.9% vs. 29.1%, respectively). Patients with UC who were obese (BMI > 30) had a higher prevalence of MM than those who were non-obese (12.6% vs. 8.3%). Conclusions: Overall, UC appears to be associated with MM. This association can be particularly observed in specific demographic groups, such as obese, African American males, or patients >64 years of age. Thus, a high degree of clinical suspicion for MM is warranted, even with minimal symptomatology, in patients with UC, in particular among elder, obese, and African American males.

show abstract

Differentiation of plasmocytic responses from myelomatous diseases on the basis of bone-marrow findings

Cited by 31 publications

References 15 publications

M-proteins, plasmacytosis and cancer

M-proteins, plasmacytosis and cancer

Review Article: Multiple Myeloma and Inflammatory Bowel Disease

Association between Multiple Myeloma and Ulcerative Colitis: A Cross-Sectional Analysis

Contact Info

Product

Resources

About